Characterization of CYP2B6 and CYP2A6 Pharmacogenetic Variation in Sub‐Saharan African Populations
Clinical Pharmacology & Therapeutics · 2024-03 · 115 (3) · 576-594
DOI: 10.1002/cpt.3124 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 20.12.2023. Verfasst von David Twesigomwe und 13 weiteren Autor:innen. Beteiligte Einrichtung: Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Hauptthemen laut MEDLINE: Pharmacogenetics, Nicotine. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHGRI NIH HHS, Wellcome Trust, National Human Genome Research Institute.
Abstract (Originalsprache)
Genetic variation in CYP2B6 and CYP2A6 is known to impact interindividual response to antiretrovirals, nicotine, and bupropion, among other drugs. However, the full catalogue of clinically relevant pharmacogenetic variants in these genes is yet to be established, especially across African populations. This study therefore aimed to characterize the star allele (haplotype) distribution in CYP2B6 and CYP2A6 across diverse and understudied sub‐Saharan African (SSA) populations. We called star alleles from 961 high‐depth full genomes using StellarPGx, Aldy, and PyPGx. In addition, we performed CYP2B6 and CYP2A6 star allele frequency comparisons between SSA and other global biogeographical groups represented in the new 1000 Genomes Project high‐coverage dataset ( n = 2,000). This study presents frequency information for star alleles in CYP2B6 (e.g., *6 and *18 ; frequency of 21–47% and 2–19%, respectively) and CYP2A6 (e.g., *4 , *9 , and *17 ; frequency of 0–6%, 3–10%, and 6–20%, respectively), and predicted phenotypes (for CYP2B6), across various African populations. In addition, 50 potentially novel African‐ancestry star alleles were computationally predicted by StellarPGx in CYP2B6 and CYP2A6 combined. For each of these genes, over 4% of the study participants had predicted novel star alleles. Three novel star alleles in CYP2A6 (* 54 , * 55 , and * 56 ) and CYP2B6 apiece, and several suballeles were further validated via targeted Single‐Molecule Real‐Time resequencing. Our findings are important for informing the design of comprehensive pharmacogenetic testing platforms, and are highly relevant for personalized medicine strategies, especially relating to antiretroviral medication and smoking cessation treatment in Africa and the African diaspora. More broadly, this study highlights the importance of sampling diverse African ethnolinguistic groups for accurate characterization of the pharmacogene variation landscape across the continent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
- Division of Human Genetics, National Health Laboratory Service, and School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
- Department of Biochemistry and Medical Genetics, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
- Neuroscience Research Program, Kleysen Institute for Advanced Medicine, Winnipeg Health Sciences Centre and Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
- Department of Pharmacology and Therapeutics, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
- Institute for Human Virology, Abuja, Nigeria.
ORCID-Profile: David Twesigomwe, Britt I Drögemöller, Galen E B Wright, Clement Adebamowo, Godfred Agongo, Palwendé R Boua, Mogomotsi Matshaba, Maria Paximadis, Michèle Ramsay, Gustave Simo, Martin C Simuunza, Caroline T Tiemessen, Zané Lombard, Scott Hazelhurst
Förderung
- NHGRI NIH HHS
- Wellcome Trust
- National Human Genome Research Institute
- Bill and Melinda Gates Foundation
Zitieren
APA
Twesigomwe, D., Drögemöller, B. I., Wright, G. E. B., Adebamowo, C., Agongo, G., Boua, P. R., Matshaba, M., Paximadis, M., Ramsay, M., Simo, G., Simuunza, M. C., Tiemessen, C. T., Lombard, Z., & Hazelhurst, S. (2024). Characterization of CYP2B6 and CYP2A6 Pharmacogenetic Variation in Sub‐Saharan African Populations. Clinical Pharmacology & Therapeutics, 115(3), 576-594. https://doi.org/10.1002/cpt.3124
Vancouver
Twesigomwe D, Drögemöller BI, Wright GEB, Adebamowo C, Agongo G, Boua PR, et al. Characterization of CYP2B6 and CYP2A6 Pharmacogenetic Variation in Sub‐Saharan African Populations. Clinical Pharmacology & Therapeutics. 2024;115(3):576-594. doi:10.1002/cpt.3124
BibTeX
@article{Twesigomwe2024,
author = {Twesigomwe, David and Drögemöller, Britt I and Wright, Galen E B and Adebamowo, Clement and Agongo, Godfred and Boua, Palwendé R and Matshaba, Mogomotsi and Paximadis, Maria and Ramsay, Michèle and Simo, Gustave and Simuunza, Martin C and Tiemessen, Caroline T and Lombard, Zané and Hazelhurst, Scott},
title = {Characterization of CYP2B6 and CYP2A6 Pharmacogenetic Variation in Sub‐Saharan African Populations},
journal = {Clinical Pharmacology & Therapeutics},
year = {2024},
volume = {115},
number = {3},
pages = {576--594},
doi = {10.1002/cpt.3124}
}
EUVIMED